Beneficial effect of pramipexole for motor function and depression in Parkinson&rsquo;s disease

Código QR

Beneficial effect of pramipexole for motor function and depression in Parkinson&rsquo;s disease

Osamu Kano1,2, Ken Ikeda2, Tetsuhito Kiyozuka2, Konosuke Iwamoto2, Hirono Ito2, Yuji Kawase2, Ryuta Sato2, Toshiki Fujioka2, Yo Araki2, Shigeji Baba2, Yasuo Iwasaki21Department of Neurology, Methodist Neurological Institute, Houston, TX, USA; 2Department of Neurology, Toho University Omori Medical C...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Osamu Kano, Ken Ikeda, Tetsuhito Kiyozuka, Konosuke Iwamoto, Hirono Ito, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/3b0f1bb172eb465f8aefe58e95819398
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Update on the use of pramipexole in the treatment of Parkinson&rsquo;s disease
por: Radu Constantinescu
Publicado: (2008)

Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson&rsquo;s disease: implications for patients
por: Antonini A, et al.
Publicado: (2011)

Sleep disorders in Parkinson&rsquo;s disease
por: Israt Jahan, et al.
Publicado: (2009)

COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson&rsquo;s disease (PD): relevance for motor and non-motor features
por: Angelo Antonini, et al.
Publicado: (2008)

Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer&rsquo;s disease receiving donepezil
por: Kano O, et al.
Publicado: (2013)

Rasagiline in treatment of Parkinson&rsquo;s disease
por: Lakshmi Nayak, et al.
Publicado: (2008)

Psychiatric disorders in primary focal dystonia and in Parkinson&rsquo;s disease
por: Fernando MV Dias, et al.
Publicado: (2011)

Current approaches to the treatment of Parkinson&rsquo;s disease
por: Joseph Jankovic, et al.
Publicado: (2008)

Update on ropinirole in the treatment of Parkinson&rsquo;s disease
por: Holly A Shill, et al.
Publicado: (2008)

Depression in Parkinson&rsquo;s disease: Health risks, etiology, and treatment options
por: Pasquale G Frisina, et al.
Publicado: (2008)

Depressive symptoms in Parkinson&rsquo;s disease and in non-neurological medical illnesses
por: Assogna F, et al.
Publicado: (2013)

Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease
por: Hametner EM, et al.
Publicado: (2012)

Ceruloplasmin and iron in Alzheimer&rsquo;s disease and Parkinson&rsquo;s disease: a synopsis of recent studies
por: Kristinsson J, et al.
Publicado: (2012)

Rivastigmine for the treatment of dementia associated with Parkinson&rsquo;s disease
por: Jennifer L Reingold, et al.
Publicado: (2007)

Parkinson&rsquo;s disease and the frequent reasons for emergency admission
por: Ozlem Guneysel, et al.
Publicado: (2008)

Did depressive symptoms affect recognition of emotional prosody in Parkinson&rsquo;s disease?
por: Adriana V&eacute;lez Feij&oacute;, et al.
Publicado: (2008)

Potential cellular and regenerative approaches for the treatment of Parkinson&rsquo;s disease
por: Emma L Lane, et al.
Publicado: (2008)

Parkinson&rsquo;s disease patients&rsquo; subjective descriptions of characteristics of chronic pain, sleeping patterns and health-related quality of life
por: Skogar &Ouml;, et al.
Publicado: (2012)

A randomized controlled trial of quetiapine for psychosis in Parkinson&rsquo;s disease
por: Paul Shotbolt, et al.
Publicado: (2009)

Impact of non-motor symptoms in Parkinson’s disease: a PMDAlliance survey
por: Hermanowicz N, et al.
Publicado: (2019)

Restless legs syndrome: differential diagnosis and management with pramipexole
por: Francesca Brindani, et al.
Publicado: (2009)

Daytime sleepiness in elderly Parkinson&rsquo;s disease patients and treatment with the psychostimulant modafinil: A preliminary study
por: Johan L&ouml;kk
Publicado: (2010)

Current options for the treatment of Paget&rsquo;s disease of the bone
por: Daniela Merlotti, et al.
Publicado: (2009)

Optimizing levodopa therapy for Parkinson&rsquo;s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
por: David J Brooks
Publicado: (2008)

Progressive Resistance Training Improves Bradykinesia, Motor Symptoms and Functional Performance in Patients with Parkinson’s Disease
por: Vieira de Moraes Filho A, et al.
Publicado: (2020)

Parkinson’s disease-associated melanin steal
por: Hinz M, et al.
Publicado: (2014)

Aripiprazole in the treatment of Huntington&rsquo;s disease: a case series
por: Andrea Ciammola, et al.
Publicado: (2008)

An update on the toxicity of A&beta; in Alzheimer&rsquo;s disease
por: J&uuml;rgen G&ouml;tz, et al.
Publicado: (2008)

Editor&rsquo;s choice: the best of 2011&ndash;2012
por: Pinder RM
Publicado: (2013)

Systematic review of the prevalence and incidence of Parkinson’s disease in the People’s Republic of China
por: Zou YM, et al.
Publicado: (2015)

The patients&rsquo; perspective: Results of a survey assessing knowledge about and attitudes toward depression in PD
por: Irene Hegeman Richard, et al.
Publicado: (2007)

Cognitive decline tracks motor progression and not disease duration in Parkinson patients
por: BD Riggeal, et al.
Publicado: (2007)

Prevalence of Parkinson’s disease and other types of Parkinsonism in Al Kharga district, Egypt
por: El-Tallawy HN, et al.
Publicado: (2013)

Neuropsychiatric symptoms in untreated Parkinson’s disease
por: Szatmari S, et al.
Publicado: (2017)

Depression and Related Factors in Patients with Parkinson’s Disease at High Altitude
por: Cao Y, et al.
Publicado: (2021)

Do neurologists in Germany adhere to the national Parkinson&#39;s disease guideline?
por: Sabrina Schr&ouml;der, et al.
Publicado: (2011)

COMPARISON EFFECT BETWEEN PEGAGAN (Centella asiatica) EXTRACT AND PRAMIPEXOLE TOWARD LOCOMOTOR ACTIVITIES, α - SYNUCLEIN, AND NRF2 EXPRESSION IN ZEBRAFISH PARKINSON MODEL
por: Ayu Trisnawati, et al.
Publicado: (2019)

Parkinson’s disease managing reversible neurodegeneration
por: Hinz M, et al.
Publicado: (2016)

Review: management of Parkinson&#39;s disease
por: Pedrosa DJ, et al.
Publicado: (2013)

Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
por: Werner Poewe, et al.
Publicado: (2010)